newswire, breaking biotechnology and pharma news

Monday, August 8, 2011

Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals (NASDAQ: BPAX), Discusses the Future of LibiGel® Following Closing of $48 Million Offering

Point Roberts, WA, LINCOLNSHIRE, Ill - August 8, 2011 - (, an investor research portal covering leading sectors including biotech and pharma stocks, features an exclusive Q&A interview with Mr. Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals (NASDAQ:BPAX), following the announcement of the closing of a $48.0 Million public offering.
BioSante plans to use the net proceeds from the offering for general corporate purposes, including funding the ongoing Phase III clinical study program for LibiGel� for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).
BioSante Pharmaceuticals Interview
Mr. Simes, following the closing of the $48 Million offering, you report use of proceeds will include ongoing Phase III clinical study program for LibiGel® for the treatment of female sexual dysfunction (FSD). How far will this take you into the study and what does this mean for investor confidence in taking this product to market?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The proceeds of the $48 million underwritten financing together with the cash we had before the transaction results in almost $80 million in cash. This cash balance is sufficient to fund the LibiGel program and BioSante through our anticipated LibiGel new drug application (NDA) submission by the end of 2012, and in fact all the way through a potential FDA approval which could come in mid-2013. This long runway was one of the key reasons for executing the transaction at this time. Another reason for executing the transaction at this time was so that in the fourth quarter of this year when we announce LibiGel efficacy data investors can concentrate on the quality of the data versus being concerned that we would need to raise money.
Mr. Simes can you tell investors what it means to BioSante to have some of the top names in Healthcare Banking, such as Jefferies backing the financing for your company to pave your way for the treatment of female sexual dysfunction?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We are happy to have had Jefferies as the lead banker on this important and well executed BioSante financing. This is our first underwritten transaction, our first financing without issuing warrants and the largest single financing we have ever executed. The institutional investors in this transaction include new and existing stockholders of BioSante, most of which concentrate in biotech/pharma investing. All of these factors are important indicators of investor confidence in BioSante.
Mr. Simes besides funding the ongoing Phase III clinical study program for LibiGel how else will BioSante use their funding proceeds?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
The vast majority of BioSante spending over the last few years has been and will continue to be funding the LibiGel Phase III clinical development program. This has been a long-term commitment of BioSante, and we believe represents a major upside for our stockholders and the women of the United States. A full 13 years after Viagra was approved for men in the United States there still is no pharmaceutical product approved by the FDA for women's sexual health. LibiGel is the only product in the world in Phase III clinical development for the treatment of hypoactive sexual desire disorder, a significant unmet medical need.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at:
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “could,” “should,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, subsequent quarterly report on Form 10-Q and final prospectus supplement dated July 28, 2011. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
For Media:
Alan Zachary
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on
Request news, updates and trading alerts on BPAX and other showcase stocks
Research more biotech stocks at the Biotech stocks Directory:
About : is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer: Disclosure:  
Source:, BioSante,
800 665 0411

No comments:

Post a Comment